LI
NGNE icon

Leap Investments’s Neurogene NGNE Stock Holding History

Leap Investments’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$302K Buy
910
+335
+58% +$87.3K 0.2% 207
2020
Q1 		$131K Buy
+575
New +$118K 0.19% 220

Other funds holding NGNE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Leap Investments's NGNE Position: Q2 2020 in Review

Leap Investments increased its Neurogene (NGNE) stake by 58% in Q2 2020, buying an estimated $87.3K and bringing the position to 910 shares worth $302K. The position accounts for 0.2% of the portfolio, ranked #207.

Leap Investments first reported a position in NGNE in Q1 2020 and has held it in 2 quarters since. 74 funds tracked by Wall St. Rank hold NGNE as of Q2 2020.

  • Leap Investments held 910 shares of Neurogene worth $302K as of Q2 2020.
  • Leap Investments bought 335 Neurogene shares in Q2 2020, an estimated $87.3K.
  • Neurogene made up 0.2% of Leap Investments's portfolio in Q2 2020, its #207 holding.
  • Leap Investments first reported a position in Neurogene in Q1 2020 and has held it in 2 quarters since.
  • 74 funds tracked by Wall St. Rank held Neurogene as of Q2 2020.

Based on Leap Investments's 13F filing for Q2 2020, filed 3 Aug 2020.